Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Major Depressive Disorder
Interventions: Placebo, fluoxetine, duloxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 44
States / cities: Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more

Conditions: Healthy
Interventions: desvenlafaxine SR, venlafaxine ER; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Depressive Disorder, Major
Interventions: JNJ-89495120, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more

Conditions: Major Depressive Episode Associated With Bipolar II Disorder
Interventions: NMRA-335140 80 mg, Placebo; Drug
Lead sponsor: Neumora Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more

Conditions: Major Depressive Disorder
Interventions: Internet Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
Interventions: Sigma-Stim, RUL LAP-ST (Low-Amplitude Pulse Seizure Therapy - Right Unilateral); Device · Procedure
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Major Depressive Disorder
Interventions: Ketamine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Bipolar Disorder, Serum Biomarkers
Interventions: MDDScoreTM; Other
Lead sponsor: University of Utah; Other
Eligibility: 13 Years to 21 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 40
States / cities: Birmingham, Alabama • Beverly Hills, California • Garden Grove, California + 36 more

Conditions: Major Depressive Disorder, Recurrent
Interventions: TMS positively correlated DLPFC, TMS to negatively correlated DLPFC; Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Depression in Adolescence, Rumination
Interventions: Mindfulness + fMRI Neurofeedback; Other
Lead sponsor: Columbia University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Depressive Disorder, Major
Interventions: Active neurofeedback, Sham neurofeedback; Behavioral
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 35 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Depression / Major Depressive Disorder, Mental Health (Depression)
Interventions: Stress Management and Resiliency Training with Qigong/Tai Chi, Healthy Living Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: LY2940094, Placebo; Drug
Lead sponsor: BlackThorn Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 10
States / cities: North Miami, Florida • Oakland Park, Florida • University Park, Florida + 7 more

Conditions: Depressive Disorder, Treatment-Resistant
Interventions: MIJ821, Placebo, Ketamine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more

Conditions: Depression, Major Depressive Disorder
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 30
States / cities: Beverly Hills, California • Encino, California • Garden Grove, California + 26 more

Conditions: Depressive Disorder, Major
Interventions: Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support; Drug · Behavioral
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 29
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more

Conditions: Major Depressive Disorder
Interventions: Riluzole, Sertraline, placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Major Depressive Disorder, Dysthymic Disorder, Alcohol-Related Disorders, Alcoholism
Interventions: Cognitive Behavioral Analysis System of Psychotherapy; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Major Depressive Disorder
Interventions: Ketamine, Placebo; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Suicidal Ideation, Major Depressive Disorder
Interventions: Belbuca Buccal Product, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Video Task, Imaginal Task; Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Depression, Major Depressive Disorder, Persistent Depressive Disorder
Interventions: Transcranial Magnetic Stimulation (TMS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

Study Evaluating the Pharmacokinetics of Venlafaxine ER and Desvenlafaxine SR in Healthy Subjects

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function

Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Investigation of Brain Network Dynamics in Depression

Mindfulness-Based fMRI Neurofeedback for Depression

Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression

Stress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms

Treatment of Reduced Heart Rate Variability Associated With Major Depression With Electroconvulsive Therapy

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Psilocybin for Major Depressive Disorder (MDD)

Riluzole Augmentation Pilot in Depression (RAPID) Trial

Clinical Trial of CBASP for Individuals With Co-occurring Chronic Depression and Alcohol Dependence

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Anti-suicidal Effects of Buprenorphine In Depressed Individuals

Heart Rate Variability in Depression

Individualized (fMRI-guided) TMS Treatment for Depression